UNCY SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Reminds Unicycive Therapeutics (UNCY) Investors of Securities Class Action Lawsuit Deadline on November 2, 2026

Faruqi & Faruqi says it is investigating potential claims against Unicycive Therapeutics and notes that a federal securities class action has been filed against the company. Investors who purchased or acquired Unicycive securities from December 29, 2025, through June 29, 2026, have until November 2, 2026, to seek appointment as lead plaintiff.

Analysis

This is a legal-solicitation notice, not evidence that the allegations have merit or that the company faces a new operating or regulatory setback. The near-term market mechanism is therefore sentiment and headline risk around the November 2 lead-plaintiff deadline; without the complaint’s allegations, a disclosed loss estimate, or a company response, the notice alone does not support a durable valuation reset. For a biotech, litigation can amplify existing financing and event risk if it undermines confidence in prior disclosures, but that is conditional—not established by this item. Over days, expect any effect to depend on whether the underlying complaint or company response adds material information. Over 1–3 months, monitor court filings and any disclosure clarifying the alleged statements, corrective event, or potential financial exposure. Over 6–18 months, the more consequential question is whether litigation affects access to capital or confidence in the clinical/regulatory investment case; this notice provides no evidence either has occurred. The contrarian point: investor-law-firm outreach is often a low-information signal, so treating it as proof of misconduct or automatically shorting UNCY risks confusing solicitation with new fundamentals.

Key Decisions for Investors

• No standalone trade on this notice. Avoid initiating a short solely on the solicitation; legal headlines can fade quickly, while biotech shares may also move on unrelated company-specific catalysts.
• Near-term watch: review the actual complaint, docket, and any Unicycive response for the alleged misstatement, the asserted corrective disclosure, and whether the claims identify a potentially material financial or operational consequence.
• Reassess exposure if filings or company disclosures indicate the dispute could impair financing access or materially change confidence in the company’s clinical/regulatory outlook; those impacts are not established here.
• Thesis against a bearish reaction: absent substantive new allegations or a company disclosure, the deadline passes without material new information and UNCY’s price action tracks its underlying biotech catalysts instead. Track relative performance and company disclosures rather than infer a price target from this notice.